A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Clinical Experts Establish 1st Ever Global Consensus for the Appropriate Use of IVUS in Peripheral Vascular Disease Interventions

First global analysis of IVUS by interventional cardiology, interventional radiology, and vascular surgery experts in peripheral vascular disease (PVD) interventions Consensus results shared at IVUS symposium by Smith Center of Outcomes Research during VIVA

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology and IVUS solutions, today announced that a worldwide committee of 40 cross-specialty medical experts achieved the first-ever consensus for the appropriate use of intravascular ultrasound (IVUS) in peripheral vascular disease (PVD) interventions. The new consensus and recommendations for use of IVUS aim to improve quality care in PVD and are based on evidence, expert practice standards, and clinical experience.

“The results of the cross-specialty expert consensus demonstrate strong support for the use of IVUS during peripheral interventions,” said Eric A. Secemsky, MD, Interventional Cardiologist at Beth Israel Deaconess Medical Center and Assistant Professor of Medicine at Harvard Medical School, Boston USA. “Future efforts need to focus on improving IVUS implementation into clinical practice and streamlining procedural workflow to help improve our patient outcomes.”

As part of Philips’ peripheral vascular portfolio, IVUS provides the visualization and guidance essential for the optimal diagnosis and treatment of patients. Using a miniaturized ultrasound transducer mounted on the tip of a catheter, it captures real-time, high-resolution images inside the vessel. IVUS imaging enables physicians to formulate patient-specific treatment plans and confirm therapy results.

Today, healthcare providers’ use of IVUS in PVD interventions is not standardized and is therefore inconsistent. The new appropriate-use expert consensus may help establish global standards of care to adopt into guidelines and improve quality care in PVD.

To achieve consensus, the broad, multi-disciplinary, global experts used a rigorous methodology. They conducted a systematic and comprehensive review of key clinical IVUS scenarios and decision-making processes before voting as world experts in the field. The results were shared at a special symposium during Vascular Interventional Advances (VIVA) 2021 (Las Vegas, USA, 5-7 October). Through this method, experts established clinical consensus to identify optimal use of IVUS and potential gaps to set a standard across clinical specialties and drive positive outcomes for patients.

“We commend these global, cross-specialty experts, on their commitment to identifying the appropriate uses of IVUS to standardize procedures in order to improve outcomes for peripheral vascular patients worldwide,” said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips. “This expert consensus sets a precedent on how patients are managed and supports Philips’ commitment to evidence-based medical guidelines as part of our pursuit of better patient outcomes, enhanced patient and staff experiences, and lower cost of care.”

Philips is the global leader in IVUS solutions which are part of the company’s comprehensive portfolio of systems, smart devices, software, and services for peripheral vascular disease with the objective of helping clinicians decide, guide, treat and confirm the right therapy for each patient during their procedure.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy